Key terms
About KURA
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest KURA news
May 06
12:30am ET
Analysts Are Bullish on These Healthcare Stocks: Relay Therapeutics (RLAY), Kura Oncology (KURA)
May 03
11:34am ET
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Kura Oncology (KURA) and Amgen (AMGN)
May 03
7:43am ET
Scotiabank Keeps Their Hold Rating on Kura Oncology (KURA)
May 03
7:33am ET
Kura Oncology reports inducement grants under Nasdaq listing rule
May 03
6:42am ET
Barclays Remains a Buy on Kura Oncology (KURA)
May 03
6:28am ET
Buy Rating Affirmed for Kura Oncology Amid Strong Financials and Promising Clinical Milestones
May 02
4:27pm ET
Kura Oncology reports Q1 EPS (59c), consensus (55c)
Apr 22
10:15am ET
Kura Oncology’s Buy Rating Affirmed by Analyst Joseph Pantginis Amid Breakthrough Therapy Designation and Promising Preclinical Data
Apr 22
7:37am ET
Kura Oncology receives breakthrough therapy designation for ziftomenib
Apr 05
7:34am ET
Kura Oncology reports inducement grants under Nasdaq listing rule
Mar 06
11:35am ET
Buy Rating Affirmed: Kura Oncology’s KO-2806 Shows Promising Clinical and Market Potential
Mar 06
7:35am ET
Kura Oncology reports first patient dosed in trial of KO-2806
Mar 01
1:02am ET
Buy Rating for Kura Oncology Amid Strong Q4 Results and Promising Ziftomenib Trials
Feb 28
10:20am ET
Analysts Are Bullish on These Healthcare Stocks: Kura Oncology (KURA), uniQure (QURE)
Feb 28
7:17am ET
Scotiabank Sticks to Their Hold Rating for Kura Oncology (KURA)
Feb 28
7:08am ET
Buy Rating for Kura Oncology: Promising Pipeline and Strategic Advantages Solidify Market Position
Feb 28
6:27am ET
Strong Buy Rating for Kura Oncology Based on Solid Financials and Promising Clinical Trials
Feb 28
5:35am ET
Kura Oncology’s Ziftomenib Shows Promising Clinical Progress with Strong Market Potential and Buy Rating
Feb 28
3:36am ET
Kura Oncology (KURA) Gets a Buy from Barclays
Feb 28
12:50am ET
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA), Lemaitre Vascular (LMAT) and Agilon Health (AGL)
Feb 27
11:57pm ET
TD Cowen Sticks to Its Buy Rating for Kura Oncology (KURA)
Feb 27
4:12pm ET
Kura Oncology reports Q4 EPS (55c), consensus (55c)
Feb 09
5:23pm ET
Kura Oncology files to sell 8.7M shares of common stock for holders
No recent press releases are available for KURA
KURA Financials
Key terms
Ad Feedback
KURA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
KURA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
